Best Compounded Semaglutide Telehealth 2026: How to Choose

What changed in 2025 and 2026

On 2025-02-21 FDA announced it would stop tolerating the compounding of semaglutide injection that had depended on its temporary flexibility, and set end dates for that flexibility [1]. Enforcement discretion for state-licensed pharmacies and physicians ended after a court denied the compounders' injunction request on 2025-04-24; for outsourcing facilities FDA said it would not act until 2025-05-22 [1]. Outsourcing facilities generally cannot compound from bulk substances unless the substance is on the outsourcing bulks list, and FDA says semaglutide is not on it [1]. FDA proposed on 2026-04-30 to exclude semaglutide from the bulks list, with no final decision made [3].

What FDA's rules allow

A state-licensed pharmacy may compound for an individual patient on a prescription, and may not compound regularly or in inordinate amounts products that are essentially copies of a commercially available drug [1]. FDA treats a product as essentially a copy of a commercially available drug when the strength is the same, similar or easily substitutable and the approved drug can be used by the same route, unless a prescriber documents a significant difference for that patient [1]. FDA also says it does not intend to take action against a compounder that fills four or fewer prescriptions of such a copy in a calendar month [1]. Adding vitamin B12 does not settle it: FDA says a semaglutide-plus-B12 product may still be a copy when the route is the same and the amounts of semaglutide and B12 are each within 10% of their respective commercial products [1].

HealthRX.com offers compounded semaglutide by prescription.

FDA's warning signs and reported problems

FDA tells consumers to watch for a seller that sends medicine that looks different from what was pictured or arrives damaged or without instructions, requires no screening and prescription by a licensed doctor, has no licensed doctor available for questions afterward, or shows a misspelled label or a pharmacy name that may be fraudulent [2]. FDA had received 990 adverse event reports for compounded semaglutide as of 2026-05-31, likely an undercount, and reports dosing errors including patients measuring wrong doses and clinicians miscalculating [2]. Semaglutide sodium and semaglutide acetate are different active ingredients from the approved drug, with no lawful basis for compounding that FDA is aware of [2].

Checking the strength against the approved labels

The Wegovy injection label runs 0.25 mg weekly for weeks 1 to 4, then 0.5 mg, 1 mg and 1.7 mg at four-week steps, maintaining at 2.4 mg or 1.7 mg from week 17; it allows up to 7.2 mg weekly for adults who have tolerated 2.4 mg for at least 4 weeks and need more weight loss [4]. Oral and injected semaglutide are not interchangeable in milligrams: oral bioavailability is about 1% to 2% versus 89% for subcutaneous injection [4].